Summary & Overview
HCPCS Q2036: Influenza Vaccine (Flulaval) IM for Ages 3+
HCPCS Level II code Q2036 denotes the Flulaval influenza vaccine (split virus) for intramuscular administration to individuals aged 3 years and older. As a product-specific vaccine code, Q2036 is used on medical claims to identify the vaccine itself rather than the administration service, which is typically reported with separate vaccine administration codes. Accurate use of product-level codes like Q2036 matters nationally for tracking vaccine utilization, supply management, and payment parity across outpatient and pharmacy sites.
Key payers commonly involved in coverage and reimbursement for this vaccine include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks for payer coverage patterns, guidance on claim composition (product versus administration reporting), and clinical context related to age indications and typical settings of service. The summary also highlights common billing modifiers and where to report the vaccine in the claim line; however, specific modifier guidance and payer-specific rules are addressed in detailed sections. Data not provided in the input are identified as such where applicable.
Billing Code Overview
HCPCS Level II code Q2036 describes the influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Flulaval). This code represents a single-dose vaccine product intended to prevent seasonal influenza in pediatric (age 3+) and adult populations.
Service type: Vaccine administration (immunization)
Typical site of service: Outpatient clinics, physician offices, pharmacies, and public health clinics for intramuscular vaccination
Clinical & Coding Specifications
Clinical Context
A 45-year-old adult presents to a primary care clinic during influenza season requesting routine immunization. The patient has no acute illness, reports prior receipt of influenza vaccine in previous years, and has no known severe allergy to vaccine components. Nursing verifies vaccine history, obtains informed consent, screens for contraindications, and documents the lot number and expiration. The vaccine Q2036 (Flulaval, split virus, intramuscular, for individuals ≥3 years) is prepared and administered intramuscularly in the deltoid. Post-vaccination observation for 15 minutes is performed for syncope risk. Documentation includes vaccine product (Q2036), date, site, route, lot number, manufacturer, and VIS (vaccine information statement) given. If the patient has an acute moderate or severe illness, administration is deferred and the encounter is coded accordingly. Billing is submitted to the patient’s insurer with appropriate modifiers if applicable (e.g., AS for clinic provided service or one of the listed modifiers if reporting unusual circumstances).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (standard reporting) | Use when no special circumstances or additional reporting modifiers apply to the vaccine administration. |